Laboratory Corporation of America Holdings (LH)
| Market Cap | 21.42B |
| Revenue (ttm) | 15.26B |
| Net Income (ttm) | 1.76B |
| Shares Out | 90.40M |
| EPS (ttm) | 18.78 |
| PE Ratio | 12.86 |
| Forward PE | 13.16 |
| Dividend | $2.16 (0.89%) |
| Ex-Dividend Date | Nov 16, 2022 |
| Volume | 739,918 |
| Open | 238.91 |
| Previous Close | 241.77 |
| Day's Range | 237.26 - 241.91 |
| 52-Week Range | 200.32 - 317.17 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 284.03 (+17.6%) |
| Earnings Date | Oct 27, 2022 |
About LH
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C ... [Read more]
Financial Performance
In 2021, LH's revenue was $16.12 billion, an increase of 15.33% compared to the previous year's $13.98 billion. Earnings were $2.38 billion, an increase of 52.77%.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for LH stock is "Buy." The 12-month stock price forecast is 284.03, which is an increase of 17.58% from the latest price.
News
Oracle Cerner Technology to Manage Hospital Labs in 10 States
Cerner's lab information systems selected to help Labcorp streamline operations and enhance patient experiences for a leading health system KANSAS CITY, Mo. , Nov. 14, 2022 /PRNewswire/ -- Oracle Cerne...
Labcorp to Speak at the Credit Suisse 31st Annual Healthcare Conference
BURLINGTON, N.C.
Why Labcorp Stock Sank by Almost 6% on Thursday
No investor likes when their company trims its guidance.
LabCorp (LH) Misses Q3 Earnings Estimates, Updates Guidance
LabCorp's (LH) organic revenues decline significantly, mainly due to major decrease in COVID-19 PCR and antibody testing sales.
LabCorp (LH) Q3 Earnings and Revenues Miss Estimates
LabCorp (LH) delivered earnings and revenue surprises of -0.64% and 5.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Labcorp's stock falls 4% after COVID-19 test sales decline in the third quarter
Shares of Labcorp LH, +0.76% tumbled 4.7% in premarket trading on Thursday after the diagnostics company said revenue in the third quarter of 2022 came in lower than expected as fewer people got PCR or ...
2 Health Care Stocks That Fit Graham's Lost Formula
U.S. market indexes rose on Thursday morning as investors were encouraged by several key earnings reports and Treasury yields continued to climb.
Analysts Estimate LabCorp (LH) to Report a Decline in Earnings: What to Look Out for
LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp CEO Adam Schechter on COVID-19, flu season, home testing advances, health equity, and more
Labcorp CEO Adam Schechter speaks about various aspects of the heath care industry at Yahoo Finance's All Markets Summit.
Labcorp Appoints Google Cloud Executive Kirsten Kliphouse to Its Board of Directors
BURLINGTON, N.C.
Labcorp Establishes Comprehensive Laboratory Relationship With Ascension
BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the completion of transactions that establish a long-term laboratory relationship with Asce...
Labcorp to Announce Third Quarter Financial Results on October 27, 2022
BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the third quarter of 2022 before the market opens on Thursday, Oct. ...
Labcorp to Speak at the Baird 2022 Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the Ba...
Labcorp Acquires Clinical Outreach Laboratory Services From RWJBarnabas Health
BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of RWJBarnabas Health's outreach laboratory business and...
10 defensive stocks that can also provide you with growth and dividends over the long term
The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.
BD, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients with Treatments
Companies combine key capabilities to advance flow cytometry as an essential companion diagnostic modality for cancer and other diseases FRANKLIN LAKES, N.J. , Aug. 9, 2022 /PRNewswire/ -- BD (Becton, D...
These 3 Companies Are Taking on Monkeypox
A vaccine maker, a therapeutics company, and a medical lab could suit a variety of investor risk profiles.
Labcorp To Spin Off Clinical Development Business
LH, $257.94; Market Capitalization: $23.3 billion), a leading global life sciences company, announced that its Board of Directors authorized a plan to spin-off Clinical Development business into an inde...
LabCorp (LH) Q2 Earnings Top Estimates, Raises '22 EPS View
LabCorp (LH) posts better-than-expected earnings in the second quarter and demonstrates continued strength in the organic Base Business.
LabCorp (LH) Q2 Earnings Beat Estimates
LabCorp (LH) delivered earnings and revenue surprises of 6.21% and 3.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Labcorp to spin off its clinical-development business
Shares of Labcorp LH, +1.03% gained 4.2% in premarket trading on Thursday after beating earnings expectations for the second quarter and announcing plans to spin off its clinical-development business, w...